These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 35681499)

  • 1. CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies.
    Marhelava K; Krawczyk M; Firczuk M; Fidyt K
    Cells; 2022 May; 11(11):. PubMed ID: 35681499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
    Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
    Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates on CAR T-cell therapy in B-cell malignancies.
    Jacoby E; Shahani SA; Shah NN
    Immunol Rev; 2019 Jul; 290(1):39-59. PubMed ID: 31355492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
    Kochenderfer JN; Rosenberg SA
    Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.
    Kiani J; Naderi M; Torabi-Rahvar M; Ranjbar A; Aghayan HR; Janzamin E; Ahmadbeigi N
    Arch Iran Med; 2019 Jan; 22(1):7-10. PubMed ID: 30821155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
    Mohty M; Gautier J; Malard F; Aljurf M; Bazarbachi A; Chabannon C; Kharfan-Dabaja MA; Savani BN; Huang H; Kenderian S; Nagler A; Perales MA
    Leukemia; 2019 Dec; 33(12):2767-2778. PubMed ID: 31690821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current perspectives on resistance to chimeric antigen receptor T-cell therapy and strategies to improve efficacy in B-cell lymphoma.
    Ong SY; Chen Y; Tan MSY; Ho AYL; Hwang WYK; Lim FLWI
    Eur J Haematol; 2024 Feb; 112(2):144-152. PubMed ID: 36987995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
    Al-Juhaishi T; Ahmed S
    Curr Hematol Malig Rep; 2021 Feb; 16(1):32-39. PubMed ID: 33630232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient's age, and tumor types.
    Montagna E; de Campos NSP; Porto VA; da Silva GCP; Suarez ER
    BMC Cancer; 2024 Aug; 24(1):1037. PubMed ID: 39174908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology and clinical application of CAR T cells for B cell malignancies.
    Davila ML; Sadelain M
    Int J Hematol; 2016 Jul; 104(1):6-17. PubMed ID: 27262700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies.
    Ying Z; He T; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Zhang C; Liu W; Deng L; Wu M; Feng F; Leng X; Du T; Qi F; Hu X; Ding Y; Lu XA; Song Y; Zhu J
    BMC Cancer; 2021 Feb; 21(1):198. PubMed ID: 33632155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
    Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond CD19 CAR-T cells in lymphoma.
    Leung WK; Ayanambakkam A; Heslop HE; Hill LC
    Curr Opin Immunol; 2022 Feb; 74():46-52. PubMed ID: 34800921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific CAR T-cells for B-cell Malignancies.
    Furqan F; Shah NN
    Expert Opin Biol Ther; 2022 Aug; 22(8):1005-1015. PubMed ID: 35653589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies.
    Cao JX; Gao WJ; You J; Wu LH; Liu JL; Wang ZX
    Cytotherapy; 2019 Jul; 21(7):769-781. PubMed ID: 31160157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.
    Perica K; Curran KJ; Brentjens RJ; Giralt SA
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1135-1141. PubMed ID: 29499327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies.
    Walti CS; Krantz EM; Maalouf J; Boonyaratanakornkit J; Keane-Candib J; Joncas-Schronce L; Stevens-Ayers T; Dasgupta S; Taylor JJ; Hirayama AV; Bar M; Gardner RA; Cowan AJ; Green DJ; Boeckh MJ; Maloney DG; Turtle CJ; Hill JA
    JCI Insight; 2021 Jun; 6(11):. PubMed ID: 33914708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
    Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
    Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.